Vaccine Info

NVX-CoV2373 SARS-CoV-2 Vaccine

NVX-CoV2373 Coronavirus Vaccine Description

NVX-CoV2373 is a prefusion protein coronavirus vaccine candidate made using Novavax’s proprietary nanoparticle technology, Matrix-M, which is an adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies.

Novavax’s patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response and helping an immunized person make antibodies against the virus.

Novavax identified NVX‑CoV2373 as its lead SARS-CoV-2 candidate following pre-clinical testing that demonstrated high immunogenicity and high levels of neutralizing antibodies.

A Phase 1 clinical trial of NVX‑CoV2373 initiated in Australia during May 2020. On August 4, 2020, Novavax announced the Phase 1 data from its Phase 1/2 clinical trial found the recombinant COVID-19 vaccine candidate adjuvanted with Matrix-M, was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera.

All subjects in this study developed anti-spike IgG antibodies after a single dose of vaccine, many of them also developing wild-type virus-neutralizing antibody responses, and after Dose 2, 100% of participants developed wild-type virus-neutralizing antibody responses. Both anti-spike IgG and viral neutralization responses compared favorably to responses from patients with clinically significant COVID‑19 disease.

Importantly, the IgG antibody response was highly correlated with neutralization titers, demonstrating that a significant proportion of antibodies were functional. The study was published on August 6, 2020.

And, the adjuvant was dose-sparing, with the lower 5 µg dose of NVX‑CoV2373 performing comparably with the 25 µg dose. Cellular immune responses were measured in a subset of participants, and NVX‑CoV2373 induced antigen-specific polyfunctional CD4+ T cell responses with a strong bias toward the Th1 phenotype (IFN-g, IL-2, and TNF-a).

 The Phase 2 portion to assess immunity, safety, and COVID-19 disease reduction is expected to begin thereafter. 

Novavax was awarded $1.6 billion by the federal government as part of Operation Warp Speed (OWS). The OWS funding is being used by Novavax to complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing, and deliver 100 million doses of NVX‑CoV2373 beginning as early as late 2020.

The Coalition for Epidemic Preparedness Innovations (CEPI) is also investing up to $388 million, and the Department of Defense is investing up to $60 million of funding to advance the clinical development of NVX‑CoV2373.

Novavax, Inc. (NVAX) is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

NVX-CoV2373 Coronavirus Vaccine Indication

NVX-CoV2373 is a vaccine candidate indicated as a SARS-CoV-2 coronavirus vaccine to prevent COVID-19 disease. In preclinical trials, NVX-CoV2373 demonstrated efficient binding with receptors targeted by the virus, a critical aspect for effective vaccine protection.

NVX-CoV2373 Coronavirus Vaccine Dosage

Novavax is evaluating two intramuscular immunizations of 5 and 25 μg NVX Cov2373, with and without its Matrix-M adjuvant, in a Phase I trial.

NVX-CoV2373 was reported stable and will allow handling in a liquid formulation that can be stored at 2°C to 8°C, allowing for successful cold chain management with existing infrastructure.

NVX-CoV2373 Coronavirus Vaccine News

August 7, 2020 - Novavax and Takeda announced a partnership for the development, manufacturing, and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure, and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 disease prevention vaccine per year.

August 7, 2020 - Several days after making some headlines with a press release about the data, the Novavax vaccine effort has published on Medrxiv. The reactions to the vaccine itself look fine. Overall, there seem to be no overt safety signs to cause any concern.

August 6, 2020 - Novavax announced a license agreement with Serum Institute of India Private Limited for the development and commercialization of NVX‑CoV2373, in low- and middle-income countries and India. This agreement excludes major upper-middle and high-income countries, for which Novavax continues to retain rights.

August 5, 2020 - NIH-Moderna investigational COVID-19 vaccine shows promise in mouse studies. The vaccine is currently being evaluated in Phase 3 clinical testing.

August 4, 2020 - Novavax announced Phase 1 data from its Phase 1/2 clinical trial of its COVID‑19 vaccine candidate, NVX‑CoV2373.

July 27, 2020 - The US government issued a federal task order reserving production capacity at one of Texas A&M University System College Station's facilities. This task order is valued at about $265 million, announced the university on July 27, 2020.

July 23, 2020 - Novavax, Inc. and FUJIFILM Diosynth Biotechnologies (FDB) announced today an agreement to manufacture bulk drug substances for NVX-CoV2373, Novavax' COVID-19 vaccine candidate. FDB's site in Morrisville, North Carolina has begun production of the first batch of NVX-CoV2373. 

July 7, 2020 - Novavax, Inc. announced that it has been selected to participate in Operation Warp Speed and has been awarded $1.6 billion by the U.S. federal government to complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing; and deliver 100 million doses of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate, as early as late 2020. 

June 15, 2020 - Novavax, Inc. announced that it has entered into an agreement to sell Series A Convertible preferred stock that could generate gross proceeds of approximately $200 million.

June 8, 2020 - Novavax announced that Gregory M. Glenn, M.D., President of Research and Development, will join other vaccine industry leaders for a panel discussion at 2020 BIO Digital. “We are seeing neutralizing titers in the 10,000 range in non-human primates." And, the company expects results and plans to start a Phase II trial, and has the capacity to manufacture 100 million doses in 2020.

June 4, 2020 - Novavax announced that the company has been awarded a contract by the U.S. Department of Defense (DoD) for the manufacturing of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 consists of a stable, prefusion protein antigen made using its proprietary nanoparticle technology and includes Novavax’s proprietary Matrix‑M™ adjuvant.

May 25, 2020 - Novavax, Inc. announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology. Preliminary immunogenicity and safety results from the Phase 1 portion of the trial are expected in July 2020.

May 13, 2020 -  Dr. Gregory Glenn's presentation at the World Vaccine Congress regarding NVX-CoV2373 Vaccine for COVID-19.

May 11, 2020 - Novavax, Inc. announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance the clinical development of NVX-CoV2373, Novavax’ coronavirus vaccine candidate against SARS-CoV-2. The additional funding from CEPI will also support the rapid scale-up of the NVX-CoV2373 vaccine antigen, as well as Novavax’s proprietary Matrix-M™ adjuvant, which is expected to enhance immune responses by stimulating high levels of neutralizing antibodies.

April 8, 2020 - Novavax, Inc, announced it has identified a coronavirus vaccine candidate, NVX-CoV2373. The NVX-CoV2373 clinical development plan combines a Phase 1/Phase 2 approach to allow rapid advancement during the current coronavirus pandemic.

March 10, 2020 - CEPI to provide an initial $4 million to accelerate vaccine development to prepare for Phase 1 clinical study.

NVX-CoV2373 Coronavirus Vaccine Clinical Trials

Clinical Trial NCT04368988: Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant. The Phase 1/2 clinical trial is being conducted in two parts.

  • The Phase 1 portion is a randomized, observer-blinded, placebo-controlled trial designed to evaluate the immunogenicity and safety of NVX‑CoV2373, both adjuvanted with Matrix‑M and unadjuvanted. The trial is enrolling approximately 130 healthy participants 18 to 59 years of age at two sites in Australia. The protocol’s two-dose trial regimen assesses two dose sizes (5 and 25 micrograms) with Matrix‑M and without.
  • The Phase 2 portion is expected to be conducted in multiple countries, including the United States, and would assess immunity, safety, and COVID‑19 disease reduction in a broader age range. The estimated completion date: July 2020.

Clinical Trial: NCT04470427: A Phase 3 Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in About 30,000 Adults Aged 18 Years and Older to Prevent COVID-19 - Last Update Posted: July 31, 2020.

  • The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.
Updated
08/08/2020 - 09:15